409 related articles for article (PubMed ID: 35140233)
1. Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection.
Zou J; Xia H; Xie X; Kurhade C; Machado RRG; Weaver SC; Ren P; Shi PY
Nat Commun; 2022 Feb; 13(1):852. PubMed ID: 35140233
[TBL] [Abstract][Full Text] [Related]
2. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
Planas D; Saunders N; Maes P; Guivel-Benhassine F; Planchais C; Buchrieser J; Bolland WH; Porrot F; Staropoli I; Lemoine F; Péré H; Veyer D; Puech J; Rodary J; Baele G; Dellicour S; Raymenants J; Gorissen S; Geenen C; Vanmechelen B; Wawina-Bokalanga T; Martí-Carreras J; Cuypers L; Sève A; Hocqueloux L; Prazuck T; Rey FA; Simon-Loriere E; Bruel T; Mouquet H; André E; Schwartz O
Nature; 2022 Feb; 602(7898):671-675. PubMed ID: 35016199
[TBL] [Abstract][Full Text] [Related]
3. Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2.
Zou J; Kurhade C; Xia H; Liu M; Xie X; Ren P; Shi PY
Nat Commun; 2022 May; 13(1):2956. PubMed ID: 35618703
[TBL] [Abstract][Full Text] [Related]
4. Sequentially immune-induced antibodies could cross-neutralize SARS-CoV-2 variants.
Lv Q; Zhou S; Qi F; Zhang Y; Li F; Liu M; Bao L
Animal Model Exp Med; 2022 Feb; 5(1):89-93. PubMed ID: 35213787
[TBL] [Abstract][Full Text] [Related]
5. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
Front Immunol; 2021; 12():793953. PubMed ID: 34899762
[TBL] [Abstract][Full Text] [Related]
6. Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model.
Halfmann PJ; Kuroda M; Armbrust T; Accola M; Valdez R; Kowalski-Dobson T; Rehrauer W; Gordon A; Kawaoka Y
Cell Rep; 2022 Feb; 38(7):110394. PubMed ID: 35139368
[TBL] [Abstract][Full Text] [Related]
7. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
[TBL] [Abstract][Full Text] [Related]
8. Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2.
Xia H; Zou J; Kurhade C; Cai H; Yang Q; Cutler M; Cooper D; Muik A; Jansen KU; Xie X; Swanson KA; Shi PY
Cell Host Microbe; 2022 Apr; 30(4):485-488.e3. PubMed ID: 35245438
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine.
Kurhade C; Zou J; Xia H; Cai H; Yang Q; Cutler M; Cooper D; Muik A; Jansen KU; Xie X; Swanson KA; Shi PY
Nat Commun; 2022 Jun; 13(1):3602. PubMed ID: 35739094
[TBL] [Abstract][Full Text] [Related]
10. Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron.
Zhu KL; Gao HX; Yao L; Rong J; Yang L; Zhang Z; Jiang P; Duan LJ; Wang GL; Dai EH; Ma MJ
J Infect Dis; 2022 Nov; 226(9):1551-1555. PubMed ID: 35429398
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.
Planas D; Bruel T; Grzelak L; Guivel-Benhassine F; Staropoli I; Porrot F; Planchais C; Buchrieser J; Rajah MM; Bishop E; Albert M; Donati F; Prot M; Behillil S; Enouf V; Maquart M; Smati-Lafarge M; Varon E; Schortgen F; Yahyaoui L; Gonzalez M; De Sèze J; Péré H; Veyer D; Sève A; Simon-Lorière E; Fafi-Kremer S; Stefic K; Mouquet H; Hocqueloux L; van der Werf S; Prazuck T; Schwartz O
Nat Med; 2021 May; 27(5):917-924. PubMed ID: 33772244
[TBL] [Abstract][Full Text] [Related]
12. Transmission and Protection against Reinfection in the Ferret Model with the SARS-CoV-2 USA-WA1/2020 Reference Isolate.
Patel DR; Field CJ; Septer KM; Sim DG; Jones MJ; Heinly TA; Vanderford TH; McGraw EA; Sutton TC
J Virol; 2021 Jun; 95(13):e0223220. PubMed ID: 33827954
[TBL] [Abstract][Full Text] [Related]
13. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
Liu J; Liu Y; Xia H; Zou J; Weaver SC; Swanson KA; Cai H; Cutler M; Cooper D; Muik A; Jansen KU; Sahin U; Xie X; Dormitzer PR; Shi PY
Nature; 2021 Aug; 596(7871):273-275. PubMed ID: 34111888
[TBL] [Abstract][Full Text] [Related]
14. A rapid real-time polymerase chain reaction-based live virus microneutralization assay for detection of neutralizing antibodies against SARS-CoV-2 in blood/serum.
Abidi SH; Imtiaz K; Kanji A; Qaiser S; Khan E; Iqbal K; Veldhoen M; Ghias K; Simas JP; Hasan Z
PLoS One; 2021; 16(12):e0259551. PubMed ID: 34890401
[TBL] [Abstract][Full Text] [Related]
15. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
16. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron.
Zhang L; Li Q; Liang Z; Li T; Liu S; Cui Q; Nie J; Wu Q; Qu X; Huang W; Wang Y
Emerg Microbes Infect; 2022 Dec; 11(1):1-5. PubMed ID: 34890524
[TBL] [Abstract][Full Text] [Related]
17. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
18. Why does the Omicron sub-variant spread faster than the original?
Callaway E
Nature; 2022 Feb; 602(7898):556-557. PubMed ID: 35177843
[No Abstract] [Full Text] [Related]
19. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M
mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511
[TBL] [Abstract][Full Text] [Related]
20. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]